Follikuláris limfóma: vizsgálatok itt: Németország
19 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Berlin, Cologne, Magdeburg
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - 1/2. fázisTaking peopleA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Where
- Essen, Giessen, Munich, Wuerzburg
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00 - 2/3. fázisTaking peopleA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Where
- Wuerzburg
- Életkor
- 18 év and over
- People
- 960 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00 - 1. fázisTaking peopleA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Where
- Berlin, München, Münster
- Életkor
- 18 év and over
- People
- 215 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00 - 1. fázisTaking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Cologne, Essen, Frankfurt Am Main
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - 3. fázisTaking peopleA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Where
- Berlin, Deggendorf, Duesseldorf, Goettingen, Hamburg, Heidelberg, Jena, Karlsruhe, Luebeck, Magdeburg, Minden, Muenster, Munich, Regensburg, Wuerzburg
- Életkor
- 18 év to 130 év
- People
- 1018 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01 - 2. fázisTaking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Berlin, Chemnitz, Essen, Jena, Wuerzburg
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - 3. fázisTaking peopleA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Where
- Essen, Frankfurt (Oder), Halle (Saale), Kiel, Mainz, Munich, Mutlangen, Neuss, Stuttgart
- Életkor
- 18 év and over
- People
- 580 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06149286 · EU 2022-503092-28-00 - 3. fázisTaking peopleA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Where
- Berlin, Dresden, Frankfurt am Main, Kiel, Mainz, Mutlangen, Stuttgart, Würzburg
- Életkor
- 18 év and over
- People
- 822 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091254 · EU 2022-502660-20-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Göttingen, München, Ulm, Würzburg
- Életkor
- 18 év and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - No phaseTaking peopleZanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- Where
- Lübeck
- Életkor
- 18 év and over
- People
- 845 worldwide
- Run by
- iOMEDICO AG
See details and how to joinNCT05326308 - 2. fázisTaking peopleCombining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Dortmund, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Greifswald, Halle Saale, Hamburg, Hamm, Heidelberg, Homburg, Jena, Karlsruhe, Kiel, Luebeck, Mainz, Marburg, Minden, Muenster, Munich, Mutlangen, Offenburg, Oldenburg, Paderborn, Regensburg, Stuttgart, Ulm
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01 - No phaseTaking peopleRegistry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
- Where
- Freiburg im Breisgau
- Életkor
- 18 év and over
- People
- 2950
- Run by
- iOMEDICO AG
See details and how to joinNCT06043011 - 3. fázisTaking peopleAcalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
- Where
- Aachen, Aalen, Amberg, Augsburg, Bamberg, Bayreuth, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Eberswalde, Essen, Esslingen am Neckar, Frankfurt am Main, Frankfurt (Oder), Giessen, Greifswald, Halle Saale, Hamburg, Heilbronn, Hildesheim, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Magdeburg, Minden, Muenster, Munich, Neuss, Nuremberg, Paderborn, Rheine, Rostock, Saarbruecken, Saarlouis, Siegen, Stuttgart, Traunstein, Trier, Ulm, Wolfsburg, Wuppertal
- Életkor
- 61 év and over
- People
- 330 worldwide
- Run by
- Universität des Saarlandes
See details and how to joinNCT05820841 · EU 2022-501187-18-00 - 2. fázisTaking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Augsburg, Berlin, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig, Muenster, Munich, Regensburg, Tuebingen
- Életkor
- 18 év to 70 év
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Where
- Augsburg, Chemnitz, Dortmund, Dresden, Duesseldorf, Erfurt, Hannover, Homburg, Jena, Muenster, Munich, Ulm, Wuerzburg
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00 - 3. fázisTaking peopleEarly Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
- Where
- Berlin, Essen, Goettingen, Hamburg, Heidelberg, Kiel, Moenchengladbach, Munich, Oldenburg, Regensburg, Rostock, Stuttgart, Tuebingen, Ulm
- Életkor
- 18 év and over
- People
- 100
- Run by
- Heidelberg University
See details and how to joinNCT05045664 · EU 2023-509278-41-00 - 1/2. fázisTaking peopleTreatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
- Where
- Heidelberg
- Életkor
- 3 év and over
- People
- 68
- Run by
- University Hospital Heidelberg
See details and how to joinNCT03676504 · EU 2024-516832-82-00